Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Hepatitis B Virus (HBV) Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The hepatitis b virus (hbv) market has experienced robust growth in recent years. It will grow from $7.31 billion in 2025 to $7.98 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. Historically, this expansion has been attributed to factors such as the high prevalence of hbv in the Asia-Pacific region, limited awareness concerning hbv treatment, low vaccination coverage in early years, a reliance on generic antiviral drugs, and an increasing incidence of chronic liver disease.
The hepatitis B virus (HBV) market is projected to experience substantial expansion over the coming years. This market is anticipated to reach $11.77 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.2%. Factors driving this growth during the forecast period include enhanced research and development in HBV treatments, the broadening scope of government vaccination initiatives, the embrace of precision medicine, escalating healthcare spending, and improvements in screening and diagnostic infrastructure. Key developments expected within this period encompass a greater uptake of antiviral therapies, the continued increase in hepatitis B vaccination programs, the creation of combination treatment approaches, a specific emphasis on managing HBV in pediatric and geriatric populations, and the broadening of screening and diagnostic services.
Get A Free Sample Report With In-Depth Market Insights:
Hepatitis B Virus (HBV) Market Growth Momentum: What Factors Are Shaping Demand?
The increasing incidence of hepatitis B infection is anticipated to propel the expansion of the hepatitis B virus market going forward. Hepatitis B, a liver infection caused by the hepatitis B virus (HBV), is preventable through vaccination. Elevated hepatitis B infection rates are likely to increase demand for diagnostic tests and available treatment options. For example, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency focused on controlling and preventing disease, injury, and disability, estimated 13,300 new hepatitis B infections and 69,800 new hepatitis C infections in 2023. Thus, the high prevalence of hepatitis B infection will drive the hepatitis B virus market.
Hepatitis B Virus (HBV) Market Segment Landscape: Which Areas Lead Development?
The hepatitis b virus (hbv) market covered in this report is segmented –
1) By Type: Acute, Chronic
2) By Treatment: Immune Modulator Drugs, Antiviral Drugs, Vaccine, Surgery
3) By Age Group: Pediatrics, Adults, Seniors
4) By End User: Medical Providers, Patients, Healthcare Payers
Subsegments:
1) By Acute HBV: Asymptomatic Acute HBV, Symptomatic Acute HBV, Severe Acute HBV
2) By Chronic HBV: Chronic Hepatitis B (HBeAg Positive), Chronic Hepatitis B (HBeAg Negative), Chronic Hepatitis B With Compensated Liver Disease, Chronic Hepatitis B With Decompensated Liver Disease, Chronic Hepatitis B With Hepatocellular Carcinoma (HCC)
Hepatitis B Virus (HBV) Market Trends Redefining Industry Growth
Leading companies in the HBV market are prioritizing the advancement of innovative therapies through clinical trials and accelerating regulatory processes to improve treatment effectiveness and secure a competitive advantage. For instance, in August 2025, Aligos Therapeutics, a US-based therapeutics company, initiated patient dosing in its Phase II B-SUPREME trial, evaluating ALG-000184, a first-in-class oral capsid assembly modulator for chronic hepatitis B. This randomized, double-blind study will enroll approximately 200 treatment-naïve adults, comparing ALG-000184 to tenofovir disoproxil fumarate over 48 weeks. The primary objective is to achieve HBV DNA levels below quantifiable limits in both HBeAg-positive and HBeAg-negative participants, with secondary evaluations assessing safety, pharmacokinetics, and antigen changes. Earlier Phase I data indicated strong antiviral activity and good tolerability, reinforcing the drug’s potential. Interim results are projected for 2026, with full topline findings expected in 2027.
Hepatitis B Virus (HBV) Market Industry Leaders And Competitive Landscape
Major companies operating in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Gilead Sciences Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arbutus Biopharma Corporation, Antios Therapeutics Inc.
View The Full Hepatitis B Virus (HBV) Market Report:
Hepatitis B Virus (HBV) Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the hepatitis B Virus (HBV) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis b virus (hbv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
